Cargando…
Mechanism-Specific Pharmacodynamics of a Novel Complex-I Inhibitor Quantified by Imaging Reversal of Consumptive Hypoxia with [(18)F]FAZA PET In Vivo
Tumors lack a well-regulated vascular supply of O(2) and often fail to balance O(2) supply and demand. Net O(2) tension within many tumors may not only depend on O(2) delivery but also depend strongly on O(2) demand. Thus, tumor O(2) consumption rates may influence tumor hypoxia up to true anoxia. R...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6952969/ https://www.ncbi.nlm.nih.gov/pubmed/31766580 http://dx.doi.org/10.3390/cells8121487 |
_version_ | 1783486542859206656 |
---|---|
author | Gammon, Seth T. Pisaneschi, Federica Bandi, Madhavi L. Smith, Melinda G. Sun, Yuting Rao, Yi Muller, Florian Wong, Franklin De Groot, John Ackroyd, Jeffrey Mawlawi, Osama Davies, Michael A. Vashisht Gopal, Y.N. Di Francesco, M. Emilia Marszalek, Joseph R. Dewhirst, Mark Piwnica-Worms, David |
author_facet | Gammon, Seth T. Pisaneschi, Federica Bandi, Madhavi L. Smith, Melinda G. Sun, Yuting Rao, Yi Muller, Florian Wong, Franklin De Groot, John Ackroyd, Jeffrey Mawlawi, Osama Davies, Michael A. Vashisht Gopal, Y.N. Di Francesco, M. Emilia Marszalek, Joseph R. Dewhirst, Mark Piwnica-Worms, David |
author_sort | Gammon, Seth T. |
collection | PubMed |
description | Tumors lack a well-regulated vascular supply of O(2) and often fail to balance O(2) supply and demand. Net O(2) tension within many tumors may not only depend on O(2) delivery but also depend strongly on O(2) demand. Thus, tumor O(2) consumption rates may influence tumor hypoxia up to true anoxia. Recent reports have shown that many human tumors in vivo depend primarily on oxidative phosphorylation (OxPhos), not glycolysis, for energy generation, providing a driver for consumptive hypoxia and an exploitable vulnerability. In this regard, IACS-010759 is a novel high affinity inhibitor of OxPhos targeting mitochondrial complex-I that has recently completed a Phase-I clinical trial in leukemia. However, in solid tumors, the effective translation of OxPhos inhibitors requires methods to monitor pharmacodynamics in vivo. Herein, (18)F-fluoroazomycin arabinoside ([(18)F]FAZA), a 2-nitroimidazole-based hypoxia PET imaging agent, was combined with a rigorous test-retest imaging method for non-invasive quantification of the reversal of consumptive hypoxia in vivo as a mechanism-specific pharmacodynamic (PD) biomarker of target engagement for IACS-010759. Neither cell death nor loss of perfusion could account for the IACS-010759-induced decrease in [(18)F]FAZA retention. Notably, in an OxPhos-reliant melanoma tumor, a titration curve using [(18)F]FAZA PET retention in vivo yielded an IC(50) for IACS-010759 (1.4 mg/kg) equivalent to analysis ex vivo. Pilot [(18)F]FAZA PET scans of a patient with grade IV glioblastoma yielded highly reproducible, high-contrast images of hypoxia in vivo as validated by CA-IX and GLUT-1 IHC ex vivo. Thus, [(18)F]FAZA PET imaging provided direct evidence for the presence of consumptive hypoxia in vivo, the capacity for targeted reversal of consumptive hypoxia through the inhibition of OxPhos, and a highly-coupled mechanism-specific PD biomarker ready for translation. |
format | Online Article Text |
id | pubmed-6952969 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-69529692020-01-23 Mechanism-Specific Pharmacodynamics of a Novel Complex-I Inhibitor Quantified by Imaging Reversal of Consumptive Hypoxia with [(18)F]FAZA PET In Vivo Gammon, Seth T. Pisaneschi, Federica Bandi, Madhavi L. Smith, Melinda G. Sun, Yuting Rao, Yi Muller, Florian Wong, Franklin De Groot, John Ackroyd, Jeffrey Mawlawi, Osama Davies, Michael A. Vashisht Gopal, Y.N. Di Francesco, M. Emilia Marszalek, Joseph R. Dewhirst, Mark Piwnica-Worms, David Cells Article Tumors lack a well-regulated vascular supply of O(2) and often fail to balance O(2) supply and demand. Net O(2) tension within many tumors may not only depend on O(2) delivery but also depend strongly on O(2) demand. Thus, tumor O(2) consumption rates may influence tumor hypoxia up to true anoxia. Recent reports have shown that many human tumors in vivo depend primarily on oxidative phosphorylation (OxPhos), not glycolysis, for energy generation, providing a driver for consumptive hypoxia and an exploitable vulnerability. In this regard, IACS-010759 is a novel high affinity inhibitor of OxPhos targeting mitochondrial complex-I that has recently completed a Phase-I clinical trial in leukemia. However, in solid tumors, the effective translation of OxPhos inhibitors requires methods to monitor pharmacodynamics in vivo. Herein, (18)F-fluoroazomycin arabinoside ([(18)F]FAZA), a 2-nitroimidazole-based hypoxia PET imaging agent, was combined with a rigorous test-retest imaging method for non-invasive quantification of the reversal of consumptive hypoxia in vivo as a mechanism-specific pharmacodynamic (PD) biomarker of target engagement for IACS-010759. Neither cell death nor loss of perfusion could account for the IACS-010759-induced decrease in [(18)F]FAZA retention. Notably, in an OxPhos-reliant melanoma tumor, a titration curve using [(18)F]FAZA PET retention in vivo yielded an IC(50) for IACS-010759 (1.4 mg/kg) equivalent to analysis ex vivo. Pilot [(18)F]FAZA PET scans of a patient with grade IV glioblastoma yielded highly reproducible, high-contrast images of hypoxia in vivo as validated by CA-IX and GLUT-1 IHC ex vivo. Thus, [(18)F]FAZA PET imaging provided direct evidence for the presence of consumptive hypoxia in vivo, the capacity for targeted reversal of consumptive hypoxia through the inhibition of OxPhos, and a highly-coupled mechanism-specific PD biomarker ready for translation. MDPI 2019-11-21 /pmc/articles/PMC6952969/ /pubmed/31766580 http://dx.doi.org/10.3390/cells8121487 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Gammon, Seth T. Pisaneschi, Federica Bandi, Madhavi L. Smith, Melinda G. Sun, Yuting Rao, Yi Muller, Florian Wong, Franklin De Groot, John Ackroyd, Jeffrey Mawlawi, Osama Davies, Michael A. Vashisht Gopal, Y.N. Di Francesco, M. Emilia Marszalek, Joseph R. Dewhirst, Mark Piwnica-Worms, David Mechanism-Specific Pharmacodynamics of a Novel Complex-I Inhibitor Quantified by Imaging Reversal of Consumptive Hypoxia with [(18)F]FAZA PET In Vivo |
title | Mechanism-Specific Pharmacodynamics of a Novel Complex-I Inhibitor Quantified by Imaging Reversal of Consumptive Hypoxia with [(18)F]FAZA PET In Vivo |
title_full | Mechanism-Specific Pharmacodynamics of a Novel Complex-I Inhibitor Quantified by Imaging Reversal of Consumptive Hypoxia with [(18)F]FAZA PET In Vivo |
title_fullStr | Mechanism-Specific Pharmacodynamics of a Novel Complex-I Inhibitor Quantified by Imaging Reversal of Consumptive Hypoxia with [(18)F]FAZA PET In Vivo |
title_full_unstemmed | Mechanism-Specific Pharmacodynamics of a Novel Complex-I Inhibitor Quantified by Imaging Reversal of Consumptive Hypoxia with [(18)F]FAZA PET In Vivo |
title_short | Mechanism-Specific Pharmacodynamics of a Novel Complex-I Inhibitor Quantified by Imaging Reversal of Consumptive Hypoxia with [(18)F]FAZA PET In Vivo |
title_sort | mechanism-specific pharmacodynamics of a novel complex-i inhibitor quantified by imaging reversal of consumptive hypoxia with [(18)f]faza pet in vivo |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6952969/ https://www.ncbi.nlm.nih.gov/pubmed/31766580 http://dx.doi.org/10.3390/cells8121487 |
work_keys_str_mv | AT gammonsetht mechanismspecificpharmacodynamicsofanovelcomplexiinhibitorquantifiedbyimagingreversalofconsumptivehypoxiawith18ffazapetinvivo AT pisaneschifederica mechanismspecificpharmacodynamicsofanovelcomplexiinhibitorquantifiedbyimagingreversalofconsumptivehypoxiawith18ffazapetinvivo AT bandimadhavil mechanismspecificpharmacodynamicsofanovelcomplexiinhibitorquantifiedbyimagingreversalofconsumptivehypoxiawith18ffazapetinvivo AT smithmelindag mechanismspecificpharmacodynamicsofanovelcomplexiinhibitorquantifiedbyimagingreversalofconsumptivehypoxiawith18ffazapetinvivo AT sunyuting mechanismspecificpharmacodynamicsofanovelcomplexiinhibitorquantifiedbyimagingreversalofconsumptivehypoxiawith18ffazapetinvivo AT raoyi mechanismspecificpharmacodynamicsofanovelcomplexiinhibitorquantifiedbyimagingreversalofconsumptivehypoxiawith18ffazapetinvivo AT mullerflorian mechanismspecificpharmacodynamicsofanovelcomplexiinhibitorquantifiedbyimagingreversalofconsumptivehypoxiawith18ffazapetinvivo AT wongfranklin mechanismspecificpharmacodynamicsofanovelcomplexiinhibitorquantifiedbyimagingreversalofconsumptivehypoxiawith18ffazapetinvivo AT degrootjohn mechanismspecificpharmacodynamicsofanovelcomplexiinhibitorquantifiedbyimagingreversalofconsumptivehypoxiawith18ffazapetinvivo AT ackroydjeffrey mechanismspecificpharmacodynamicsofanovelcomplexiinhibitorquantifiedbyimagingreversalofconsumptivehypoxiawith18ffazapetinvivo AT mawlawiosama mechanismspecificpharmacodynamicsofanovelcomplexiinhibitorquantifiedbyimagingreversalofconsumptivehypoxiawith18ffazapetinvivo AT daviesmichaela mechanismspecificpharmacodynamicsofanovelcomplexiinhibitorquantifiedbyimagingreversalofconsumptivehypoxiawith18ffazapetinvivo AT vashishtgopalyn mechanismspecificpharmacodynamicsofanovelcomplexiinhibitorquantifiedbyimagingreversalofconsumptivehypoxiawith18ffazapetinvivo AT difrancescomemilia mechanismspecificpharmacodynamicsofanovelcomplexiinhibitorquantifiedbyimagingreversalofconsumptivehypoxiawith18ffazapetinvivo AT marszalekjosephr mechanismspecificpharmacodynamicsofanovelcomplexiinhibitorquantifiedbyimagingreversalofconsumptivehypoxiawith18ffazapetinvivo AT dewhirstmark mechanismspecificpharmacodynamicsofanovelcomplexiinhibitorquantifiedbyimagingreversalofconsumptivehypoxiawith18ffazapetinvivo AT piwnicawormsdavid mechanismspecificpharmacodynamicsofanovelcomplexiinhibitorquantifiedbyimagingreversalofconsumptivehypoxiawith18ffazapetinvivo |